Publications

Irfan's google scholar profile:

    2024:

  1. Abhijit Parolia, Sanjana Eyunni, Brijesh Kumar Verma, Eleanor Young, Yihan Liu, Lianchao Liu, James George, Shweta Aras, Chandan Kanta Das, Rahul Mannan, Reyaz ur Rasool, Erick Mitchell-Velasquez, Somnath Mahapatra, Jie Luo, Sandra E. Carson, Lanbo Xiao, Prathibha R. Gajjala, Sharan Venkatesh, Mustapha Jaber, Xiaoju Wang, Tongchen He, Yuanyuan Qiao, Matthew Pang, Yuping Zhang, Jean Ching-Yi Tien, Micheala Louw, Mohammed Alhusayan, Xuhong Cao, Fengyun Su, Omid Tavana, Caiyun Hou, Zhen Wang, Ke Ding, Arul M. Chinnaiyan & Irfan A. Asangani. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nat Genet (2024). https://doi.org/10.1038/s41588-024-01893-6. Nature Genetics 2024. https://doi.org/10.1038/s41588-024-01893-6

  2. Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity. Nature Communications 2024 Feb 26;15(1):1761. doi: 10.1038/s41467-024-45939-z. PMID: 38409161; PMCID: PMC10897393.

    3. 2023:

  3. Reyaz ur Rasool, Caitlin M. O’Connor, Chandan Kanta Das, Mohammed Alhusayan, Brijesh Kumar Verma, Sehbanul Islam, Ingrid E. Frohner, Qu Deng, Erick Mitchell-Velasquez, Jaya Sangodkar, Aqila Ahmed, Sarah Linauer, Ingrid Mudrak, Jessica Rainey, Kaitlin P. Zawacki, Tahra K. Suhan, Catherine G. Callahan, Ryan Rebernick, Ramakrishnan Natesan, Javed Siddiqui, Guido Sauter, Dafydd Thomas, Shaomeng Wang, Derek J. Taylor, Ronald Simon, Marcin Ciesli, Arul M. Chinnaiyan, Luca Busino, Egon Ogris, Goutham Narla & Irfan A. Asangani. Nature Communications 14, 5253 (2023). doi: https://doi.org/10.1038/s41467-023-40760-6

  4. Walter DM, Gladstein AC, Doerig KR, Natesan R, Baskaran SG, Gudiel AA, Adler KM, Acosta JO, Wallace DC, Asangani IA, Feldser DM. Commun Biol. 2023. doi: 10.1038/s42003-023-04618-3. PMID: 36899051

    5. 2022:

  5. Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, Grünewald T, Asangani IA. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell Reports. 2022 Jun 14;39(11):110971. doi: 10.1016/j.celrep.2022.110971. PMID: 35705030.

    6. 2021:

  6. R ur Rasool, Reyaz, Ramakrishnan Natesan, and Irfan A. Asangani. "Toppling the HAT to Treat Lethal Prostate Cancer." Cancer Discovery 11.5 (2021): 1011-1013.

  7. Qu Deng, Reyaz ur Rasool, Ronnie M. Russell, Ramakrishnan Natesan, Irfan A. Asangani, Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19, iScience, Volume 24, Issue 3, 2021, 102254, ISSN 2589-0042, https://doi.org/10.1016/j.isci.2021.102254.

  8. Gollavilli, P.N., Parma, B., Siddiqui, A. et al. The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter. Oncogene 40, 2309–2322 (2021). https://doi.org/10.1038/s41388-021-01708-6

  9. Asangani I, Blair IA, Van Duyne G, Hilser VJ, Moiseenkova-Bell V, Plymate S, Sprenger C, Wand AJ, Penning TM. Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. Journal of Biological Chemistry . 2021 Jan 9;296:100240. doi: 10.1074/jbc.REV120.012411. Epub ahead of print. PMID: 33384381; PMCID: PMC7949100.

  10. Siddiqui MA, Gollavilli PN, Ramesh V, Parma B, Schwab A, Vazakidou ME, Natesan R, Saatci O, Rapa I, Bironzo P, Schuhwerk H, Asangani IA, Sahin O, Volante M, Ceppi P. Thymidylate synthase drives the phenotypes of epithelial-to- mesenchymal transition in non-small cell lung cancer. British Journal of Cancer . 2020 Oct 7. doi: 10.1038/s41416-020-01095-x. Epub ahead of print. PMID: 33024270.

    11. 2020:

  11. Penning TM, Asangani IA, Sprenger C, Plymate S. Intracrine androgen biosynthesis and drug resistance. Cancer Drug Resist. 2020 Nov 3;3(4):912-929. doi: 10.20517/cdr.2020.60. PMID: 35582223; PMCID: PMC8992556.

  12. Chen J, Harding SM, Natesan R, Tian L, Benci JL, Li W, Minn AJ, Asangani IA, Greenberg RA. Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA- Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses. Cell Reports. 2020 Sep 1;32(9):108080. doi: 10.1016/j.celrep.2020.108080. PMID: 32877684; PMCID: PMC7530826.

  13. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. Nature Genetics. 2020 Aug;52(8):778-789. doi: 10.1038/s41588-020-0648-8. Epub 2020 Jul 13. PMID: 32661416; PMCID: PMC7454228.

  14. Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu NV, Yamazoe T, Lin JH, Merrell AJ, Sela Y, Thomas SK, Jiang Y, Plesset JB, Miller EM, Shi J, Garcia BA, Lowe SW, Asangani IA, Stanger BZ. Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer Discovery. 2020 Jun;10(6):854-871. doi: 10.1158/2159-8290.CD-19-1299. Epub 2020 Mar 18. PMID: 32188706; PMCID: PMC7269857.

  15. Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. Cell. 2020 Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12. PMID: 32169218; PMCID: PMC7194250.

    16. 2019:

  16. Natesan R, Aras S, Effron SS, Asangani IA. Epigenetic Regulation of Chromatin in Prostate Cancer. Advances in Experimental Medicine and Biology. 2019;1210:379-407. doi: 10.1007/978-3-030-32656-2_17. PMID: 31900918.

  17. Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell- Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discovery. 2019 Nov;9(11):1538-1555. doi: 10.1158/2159-8290.CD-19-0189. Epub 2019 Aug 29. PMID: 31466944; PMCID: PMC7202356.

  18. Kregel S, Malik R, Asangani IA, Wilder-Romans K, Rajendiran T, Xiao L, Vo JN, Soni T, Cieslik M, Fernadez-Salas E, Zhou B, Cao X, Speers C, Wang S, Chinnaiyan AM. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 2019 Jul 1;25(13):4038-4048. doi: 10.1158/1078-0432.CCR-18-3776. Epub 2019 Mar 27. PMID: 30918020; PMCID: PMC6606381.

  19. Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P. Thymidylate synthase maintains the de- differentiated state of triple negative breast cancers. Cell Death & Differentiation. 2019 Nov;26(11):2223-2236. doi: 10.1038/s41418-019-0289-6. Epub 2019 Feb 8. PMID: 30737477; PMCID: PMC6888897.

    20. 2018:

  20. Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. Cancer Research. 2018 Aug 15;78(16):4760-4773. doi: 10.1158/0008-5472.CAN-18-0484. Epub 2018 Jun 13. PMID: 29898995.

  21. Aishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, Irfan A. Asangani, Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer, Cell Reports, Volume 22, Issue 9, 2018, Pages 2236-2245, ISSN 2211-1247, https://doi.org/10.1016/j.celrep.2018.02.011.

  22. Stypulkowski E, Asangani IA, Witze ES. The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division. Science Signaling. 2018 Jan 2;11(511):eaam8705. doi: 10.1126/scisignal.aam8705. PMID: 29295957; PMCID: PMC5914505.

    23. 2017:

  23. Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, Manne U, Sonpavde G, Netto GJ, Gordetsky J, Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Mol Cancer Res. 2018 Jul;16(7):1125-1137. doi: 10.1158/1541-7786.MCR-17-0230. Epub 2017 Oct 12. Erratum in: Molecular Cancer Research. 2018 Jul;16(7):1205-1206. PMID: 29025958; PMCID: PMC5897228.

  24. Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell. 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001. Erratum for: Cancer Cell. 2017 Apr 10;31(4):532-548.e7. PMID: 28609659.

    25. 2016:

  25. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara- Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Molecular Cancer Research. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20. PMID: 26792867; PMCID: PMC4834259.

    26. 2005-2015:

  26. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080. PMID: 26325560; PMCID: PMC4758114.

  27. Scanlon CS, Banerjee R, Inglehart RC, Liu M, Russo N, Hariharan A, van Tubergen EA, Corson SL, Asangani IA, Mistretta CM, Chinnaiyan AM, D'Silva NJ. Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. Nature Communications. 2015 Apr 28;6:6885. doi: 10.1038/ncomms7885. PMID: 25917569; PMCID: PMC4476386.

  28. Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine. 2015 Apr;21(4):344-52. doi: 10.1038/nm.3830. Epub 2015 Mar 30. PMID: 25822367; PMCID: PMC4390530.

  29. Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clinical Cancer Research. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9. PMID: 25754347; PMCID: PMC4976600.

  30. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Molecular Cancer Research. 2014 Aug;12(8):1081-7. doi: 10.1158/1541-7786.MCR-14-0257. Epub 2014 Jul 16. PMID: 25030374; PMCID: PMC4135019.

  31. Alluri PG, Asangani IA, Chinnaiyan AM. BETs abet Tam-R in ER-positive breast cancer. Cell Research. 2014 Aug;24(8):899-900. doi: 10.1038/cr.2014.90. Epub 2014 Jul 8. PMID: 25001387; PMCID: PMC4123300.

  32. Asangani IA, Chinnaiyan AM. BETting on a new prostate cancer treatment. Cell Cycle. 2014;13(13):2015-6. doi: 10.4161/cc.29459. Epub 2014 Jun 6. PMID: 24905827; PMCID: PMC4111688.

  33. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23. PMID: 24759320; PMCID: PMC4075966.

  34. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014 Mar 30;5(6):1434-8. doi: 10.18632/oncotarget.1846. PMID: 24727738; PMCID: PMC4039221.

  35. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics. 2013 Nov;45(11):1392-8. doi: 10.1038/ng.2771. Epub 2013 Sep 29. PMID: 24076601; PMCID: PMC3812362.x

  36. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia. 2013 May;15(5):491-501. doi: 10.1593/neo.13314. PMID: 23633921; PMCID: PMC3638352.

  37. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Molecular Cell. 2013 Jan 10;49(1):80-93. doi: 10.1016/j.molcel.2012.10.008. Epub 2012 Nov 15. PMID: 23159737; PMCID: PMC3547524.

  38. Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia. 2012 Oct;14(10):905-14. doi: 10.1593/neo.121192. PMID: 23097625; PMCID: PMC3479836.

  39. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012 Sep;3(9):1011-25. doi: 10.18632/oncotarget.622. PMID: 22948084; PMCID: PMC3663613.

  40. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR, Lonigro RJ, Iyer MK, Barrette T, Shanmugam A, Dhanasekaran SM, Palanisamy N, Chinnaiyan AM. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell. 2012 Jun 22;149(7):1622-34. doi: 10.1016/j.cell.2012.04.041. PMID: 22726445; PMCID: PMC3597446.

  41. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125. PMID: 22722839; PMCID: PMC3396711.

  42. Leupold JH, Asangani IA, Mudduluru G, Allgayer H. Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4 regulators. Bioscience Reports. 2012 Jun;32(3):281-97. doi: 10.1042/BSR20110045. PMID: 22111549.

  43. Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discovery. 2011 Jun;1(1):35-43. doi: 10.1158/2159-8274.CD-10-0022. Epub 2011 Jun 1. PMID: 22140652; PMCID: PMC3227139.

  44. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis- Filho JS, Kumar-Sinha C, Chinnaiyan AM. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580. PMID: 22101766; PMCID: PMC3233654.

  45. Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S, Chinnaiyan AM. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011 Aug 16;20(2):187-99. doi: 10.1016/j.ccr.2011.06.016. PMID: 21840484; PMCID: PMC3157014.

  46. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology. 2011 Jul 31;29(8):742-9. doi: 10.1038/nbt.1914. PMID: 21804560; PMCID: PMC3152676.

  47. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557. PMID: 21575865; PMCID: PMC3113473.

  48. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM. Therapeutic targeting of SPINK1-positive prostate cancer. Science Translational Medicine. 2011 Mar 2;3(72):72ra17. doi: 10.1126/scitranslmed.3001498. PMID: 21368222; PMCID: PMC3211047.

  49. Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Bioscience Reports. 2011 Jun;31(3):185-97. doi: 10.1042/BSR20100065. PMID: 20815812.

  50. Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. International Journal of Cancer. 2010 Sep 1;127(6):1475-85. doi: 10.1002/ijc.25315. PMID: 20232396.

  51. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Research. 2009 Mar 15;69(6):2461-70. doi: 10.1158/0008-5472.CAN-08-3236. Epub 2009 Mar 10. PMID: 19276367.

  52. Limaye AM, Asangani I, Kalyani T, Kondaiah P. Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate. J Biosci. 2008 Jun;33(2):209-20. doi: 10.1007/s12038-008-0038-3. PMID: 18535355.

  53. Asangani IA, Rasheed SA, Leupold JH, Post S, Allgayer H. NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1 (CAPNS1) gene. Gene. 2008 Feb 29;410(1):197-206. doi: 10.1016/j.gene.2007.12.009. Epub 2007 Dec 23. PMID: 18234454.

  54. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008 Apr 3;27(15):2128-36. doi: 10.1038/sj.onc.1210856. Epub 2007 Oct 29. PMID: 17968323.

  55. Limaye AM, Asangani I, Bora N, Kondaiah P. Novel flutamide regulated genes in the rat ventral prostate: differential modulation of their expression by castration and flutamide treatments. Asian Journal of Andrology. 2007 Nov;9(6):801-8. doi: 10.1111/j.1745-7262.2007.00293.x. PMID: 17968466.

  56. Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Molecular Cancer Research. 2007 May;5(5):485-96. doi: 10.1158/1541-7786.MCR-06-0211. PMID: 17510314

  57. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 2007 Jul 5;26(31):4550-62. doi: 10.1038/sj.onc.1210234. Epub 2007 Feb 12. PMID: 17297470.

  58. Wang H, Yan C, Asangani I, Allgayer H, Boyd DD. Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene. 2007 Mar 29;26(14):2058-70. doi: 10.1038/sj.onc.1210003. Epub 2006 Sep 25. PMID: 17001307.

  59. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clinical Cancer Research. 2005 Dec 15;11(24 Pt 1):8538-48. doi: 10.1158/1078-0432.CCR-05-0786. PMID: 16361535.